SITCO Pharma

sitcopharma.com

Saudi International Trading Company Ltd. (SITCO Pharma), is engaged in the Pharmaceutical distribution business in Saudi Arabia. The company, formed in 1990, is considered a leader in the field of pharmaceutical distribution in the Kingdom of Saudi Arabia. Representing several major multinational pharmaceutical companies, SITCO Pharma has quickly established the standards for excellence in its field. The management of SITCO Pharma includes 8 senior managers, each with an average of over 13 years of service and experience in Saudi Arabia. The rapid growth of SITCO Pharma is a testimony to the commitment and dedication of management and staff.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

EYEPOINT PHARMACEUTICALS COMPLETES ENROLLMENT IN OVERSUBSCRIBED PHASE 2 DAVIO 2 CLINICAL TRIAL OF EYP-1901 FOR MAINTENANCE TREATMENT OF WET AMD

Globenewswire | March 28, 2023

news image

EyePoint Pharmaceuticals, Inc. a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it has completed enrollment in the Phase 2 "Durasert® and Vorolanib in Ophthalmology 2" (DAVIO 2) clinical trial evaluating EYP-1901 as a potential six-month maintenance treatment for wet age-related macular degeneration (wet AMD). The trial exceeded its original target of 144 patients, enrolling a total...

Read More

Business Insights

ELEMENT FURTHER EXPANDS ITS LIFE SCIENCES TESTING BUSINESS WITH ADDITIONAL PHARMACEUTICAL AND BIOTECH TESTING CAPABILITIES IN NORTH AMERICA AND EUROPE

Element Materials Technology | January 15, 2022

news image

Element Materials Technology (Element) completed its sixth life sciences-focused acquisition of 2021, with the formal completion of the acquisition of JMI Laboratories. Element has now built out its expertise and capability for pharmaceutical and biopharmaceutical customers, expanding to a team of more than 1,000 experts in 23 facilities across North America and Europe. This significant step change in pharmaceutical and medical testing capabilities from Element forms part of its b...

Read More

Business Insights

PRIME MEDICINE EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS TO SUPPORT CONTINUED GROWTH AND ADVANCEMENT OF PRIME EDITING TECHNOLOGY AND PORTFOLIO

Prime Medicine | July 29, 2022

news image

Prime Medicine, Inc. a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying Prime Editing technology “Prime Medicine is advancing a first-of-its-kind technology intended to expand the number of patients who may benefit from genetic medicines. We are thrilled to welcome Richard, Niamh and Fubao to the team. Together, they bri...

Read More

PHARMACY MARKET

AQUESTIVE THERAPEUTICS RECEIVES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM IN PEDIATRIC PATIENTS

GlobeNewswire | September 12, 2023

news image

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced acceptance by the U.S. Food and Drug Administration (FDA) of the Company’s NDA for Libervant™ (diazepam) Buccal Film in pediatric patients between two and ...

Read More
news image

Business Insights, PHARMACY MARKET

EYEPOINT PHARMACEUTICALS COMPLETES ENROLLMENT IN OVERSUBSCRIBED PHASE 2 DAVIO 2 CLINICAL TRIAL OF EYP-1901 FOR MAINTENANCE TREATMENT OF WET AMD

Globenewswire | March 28, 2023

EyePoint Pharmaceuticals, Inc. a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it has completed enrollment in the Phase 2 "Durasert® and Vorolanib in Ophthalmology 2" (DAVIO 2) clinical trial evaluating EYP-1901 as a potential six-month maintenance treatment for wet age-related macular degeneration (wet AMD). The trial exceeded its original target of 144 patients, enrolling a total...

Read More
news image

Business Insights

ELEMENT FURTHER EXPANDS ITS LIFE SCIENCES TESTING BUSINESS WITH ADDITIONAL PHARMACEUTICAL AND BIOTECH TESTING CAPABILITIES IN NORTH AMERICA AND EUROPE

Element Materials Technology | January 15, 2022

Element Materials Technology (Element) completed its sixth life sciences-focused acquisition of 2021, with the formal completion of the acquisition of JMI Laboratories. Element has now built out its expertise and capability for pharmaceutical and biopharmaceutical customers, expanding to a team of more than 1,000 experts in 23 facilities across North America and Europe. This significant step change in pharmaceutical and medical testing capabilities from Element forms part of its b...

Read More
news image

Business Insights

PRIME MEDICINE EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS TO SUPPORT CONTINUED GROWTH AND ADVANCEMENT OF PRIME EDITING TECHNOLOGY AND PORTFOLIO

Prime Medicine | July 29, 2022

Prime Medicine, Inc. a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying Prime Editing technology “Prime Medicine is advancing a first-of-its-kind technology intended to expand the number of patients who may benefit from genetic medicines. We are thrilled to welcome Richard, Niamh and Fubao to the team. Together, they bri...

Read More
news image

PHARMACY MARKET

AQUESTIVE THERAPEUTICS RECEIVES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM IN PEDIATRIC PATIENTS

GlobeNewswire | September 12, 2023

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced acceptance by the U.S. Food and Drug Administration (FDA) of the Company’s NDA for Libervant™ (diazepam) Buccal Film in pediatric patients between two and ...

Read More